MWLA Chapter Update: Goals and Celebrations

I am honored to be leading the Midwest Lipid Association this year. I started working for Ohio State 25 years ago and had a variety of teaching duties with medical students, residents, and fellows with a primary emphasis on psychiatry and cardiovascular prevention. I was asked to start a Lipid Clinic at OSU in 2005.I was initially hesitant to add something else to my existing duties. To help me make this decision, I was connected with Ralph La Forge at Duke. He and John Guyton were so helpful and kind during my visits with them, showing the ins and outs of their own clinic. They invigorated me to start the Lipid Clinic operation at OSU alongside Margie Hevezi, PharmD, CDE, CLS who is still at OSU. The decision to open the clinic turned out to be a great one. Subsequently, I joined the NLA, and have been a member for more than 18 years.

I moved to OhioHealth in 2012 and receive referrals to our Lipid Clinic from the largest pool of cardiovascular patients from any system in Ohio. I am fortunate to have an excellent supporting team including 3 other physicians (Kavita Sharma, Meg Morrison, John Hatanelas), 2 pharmacists (Sharon Starling and Adam Gonyeau), and one certified nurse specialist (Joyce Morckel), all of whom have been certified by ABCL or ACCL.

We are active in multiple clinical trials and also have been honored to work closely with the Family Heart Foundation on quality improvement projects FIND FH and now FIND LP(a) along with the CASCADE Registry. We now have another Midwest Lipid Association representative working with these Family Heart Foundation projects, Julie Clary at Indiana University.

I value the relationships that have been developed in working on these projects along with all of the wonderful NLA members that have been a source of inspiration for many years.

As a chapter, we should continue Dr. James Trippi’s efforts which have been geared towards improving access to cardiovascular prevention in a cost-effective manner. This includes improving access to our most dramatic (when it comes to improved outcomes) pharmacologic treatment, PCSK9i, and breaking down the restrictions for patient assistance.

We also need to focus our efforts on appropriate evaluation and treatment for younger adults who are at risk for cardiovascular events. We need to move away from waiting until patients are middle aged and then primarily rely on a risk equation to determine the need for pharmacologic treatment. This is still an all-too-prevalent tradition within primary care residencies and in general.  We have made some progress in moving away from this, but more is needed.  

Learning to appropriately utilize AI assisted imaging and polygenic risk scoring for CAD (especially in young adults) to improve risk categorization and treatment decision making seems quite exciting in my view.

I want to take a moment to shout out all the incredible work already being done by MWLA Members. Our inaugural MWLA Meets recurring CME webinar series was hosted Michael Davidson, MD, where he discussed novel developments of Obacetripib. It was well attended, and the discussion was fascinating. We look forward to hosting more of these in the coming weeks.

Mazhar Afaq, MD, Director of Cardiovascular Prevention at the University of Kansas Health System and PI for the V2P study has recently published: Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid

Yarrarapu SNS, Goyal A, Venkata VS, Panchal V, Sivasubramanian BP, Du DT, Jakulla RS, Pamulapati H, Afaq MA, Owens S, Dalia T.  J Cardiol. 2024 Mar 22:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Epub ahead of print. PMID: 38521120.

Alan Brown, MD, MNLA and Patrick Moriarty, MD, FNLA were featured faculty at Annual Scientific Sessions this past June. Several MWLA members presented abstracts live in Las Vegas:

  1. Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia - Elizabeth Wolfe, MD, Ernst Schaefer, MD, Nigel Paneth, MD, George Abela, MD, Daniel Zhao, PhD, Karl Hansen, MD, Andrea Ott, MS, Marianna Fernandes, BS, Robert Wild, MD
  2. Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome - Annie Skariah, MD, Garnet Meier, MD, Nataliya Pyslar, MD, Sylvia Chlebek, DO
  3. Assessment of Unmet Clinical Needs and Healthcare Resource Use among Statin-Treated Patients with or at Risk of Developing ASCVD - Bob Rambo, MBA, Brian Leinwand, PhD, Ahan Ali, BS, Dushyant Katariya, PhD, Andrew Hsieh, PharmD
  4. Clinical Outcomes and Mortality in Heart Failure and Chronic Kidney Disease Patients Admitted With Non-Variceal Upper Gastrointestinal Bleeding - Mohamad Hijazi, MD, Mhd Kutaiba Albuni, MD, Bassel Bitar, MD, Godbless Ajenaghughrure, MD, Amin Eshghabadi, MD, Kamal Shemisa, MD, Fayaz Khan, MD, M Kenan Rahima, MD
  5. Clinical Outcomes in Patients Admitted with Acute Coronary Syndrome Affected by Protein Calorie Malnutrition - Kenan Rahima, MD, Gregory Pierce, BS, Sila Faxas, MD, Borna Mansouri, MD, Maneet Multani, MD, Joseph Alfeghaly, MD, Muayad AlZamara, MD, Mohammad Amin Eshghabadi, MD
  6. Clinical Outcomes in Patients admitted with Diabetes Mellitus and Chronic Kidney Disease Affected by Non-Alcoholic Fatty Liver Disease - Mohamad Hijazi, MD, Mhd Kutaiba Albuni, MD, Bassel Bitar, MD, Godbless Ajenaghughrure, MD, Amin Eshghabadi, MD, Fayaz Khan, MD, Kamal Shemisa, MD, M Kenan Rahima, MD
  7. Patients Admitted with Acute pancreatitis and Dyslipidemia Affected by Non-Alcoholic Fatty Liver Disease are Associated with Worse Clinical Outcomes - Mohamad Hijazi, MD, Mhd Kutaiba Albuni, MD, Godbless Ajenaghughrure, MD, Bassel Bitar, MD, Amin Eshghabadi, MD, Fayaz Khan, MD, M Kenan Rahima, MD
  8. Protein Calorie Malnutrition Effect on Clinical Outcomes And Resource Utilization in Patients Admitted with Acute Pancreatitis And Dyslipidemia - Mohamad Hijazi, MD, Mhd Kutaiba Albuni, MD, Bassel Bitar, MD, Amin Eshghabadi, MD, Fayaz Khan, MD, Kamal Shemisa, MD, Godbless Ajenaghughrure, MD, M Kenan Rahima, MD
  9. Xanthelasma Associated with Defective Reverse Cholesterol Transport, Resolution with Rosuvastatin/Ezetimibe: A Case Report - Michael Doyle, MD
  10. Real World Experience with Inclisiran in an Academic Medical Center - Kelly Bartsch, PharmD, Erica Davidson, PharmD, Aaron Bagnola, PharmD, Laxmi Mehta, MD, John Larry, MD, Wesley Milks, MD, Angelique Oakley, PharmD
  11. Atrial Fibrillation Outcome in Patients with Metabolic Syndrome - Francisco Somoza-Cano, MD, Brittany Smith, BS, Michael Fatuyi, MD, Henry Egbuchiem, MD, Nkemputaife Onyechi, MD, Joseph Amoah, MD
  12. Differences in Clinical Outcomes between Non-Obese Caucasian and Hispanic Populations Who have Hyperlipidemia - Leonid Khokhlov, MD, Mehwish Kishore, MD, Mehnaaz Ali, MPH, Sam Miller, MD, Kamal Shemisa, MD, Sindhu Kishore, MD
  13. The Outcome of Coronary Artery Bypass Graft in Patient with Prediabetes - Brittany Smith, BS, Francisco Somoza-Cano, MD, Michael Fatuyi, MD, Henry Egbuchiem, MD, Nkemputaife Onyechi, MD, Joseph Amoah, MD
  14. Differences in Clinical - Outcomes between Non-Obese Caucasian and Asian Populations Who have Hyperlipidemia - Leonid Khokhlov, MD, Mehwish Kishore, MD, Kamal Shemisa, MD, Godbless Ajenaghughrure, MD, Sindhu Kishore, MD
  15. Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia - Leonid Khokhlov, MD, Gehna Kishore, MD, Godbless Ajenaghughrure, MD, Kamal Shemisa, MD, Sindhu Kishore, MD
  16. Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia - Leonid Khokhlov, MD, Gehna Kishore, MD, Godbless Ajenaghughrure, MD, Kamal Shemisa, MD, Sindhu Kishore, MD
  17. Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles - Andrew Hsieh, PharmD, Marc Ditmarsch, MD, Douglas Kling, MBA, Danielle Curcio, MBA, Mary Dicklin, PhD, John Kastelein, MD, Michael Davidson, MD
  18. Differences in Clinical Outcomes Between Non-Obese Caucasians and African American Populations with Hyperlipidemia - Leonid Khokhlov, MD, Mehwish Kishore, MD, Kamal Shemisa, MD, Mehnaaz Ali, MPH, Sam Miller, MD, Sindhu Kishore, MD
  19. Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis - Andrew K Hsieh, PharmD

Article By:

Scott Merryman, MD, FNLA

MWLA Chapter President

Lipid Clinic Director

OhioHealth

Columbus, OH

0
No votes yet